1605-89-6 Usage
Originator
Myagen,Upjohn
Uses
Synthetic anabolic; epimeric with Calusterone (C148900).
Controlled substance (anabolic steroid).
Manufacturing Process
A mixture of 0.4 g of cuprous chloride, 20 ml of 4 M methylmagnesium
bromide in ether and 60 ml of redistilled tetrahydrofuran was stirred and
cooled in an ice bath during the addition of a mixture of 2.0 g of 6-dehydro-
17-methyltestosterone, 60 ml of redistilled tetrahydrofuran and 0.2 g of
cuprous chloride. The ice bath was removed and stirring was continued for 4
h. Ice and water were than carefully added, the solution acidified with 3 N
hydrochloric acid and extracted several times with ether. The combined ether
extracts were washed with a brine-sodium carbonate solution, brine and then g column of magnesium silicate (Florisil) packed wet with hexanes
(Skellysolve B). The column was eluted with 250 ml of hexanes, 0.5 liter of
2% acetone, two liters of 4% acetone and 3.5 L of 6% acetone in hexanes.
The residues from fractions 8 to 16 were combined and rechromatographed
over a 125.0 g column of magnesium silicate. The column was eluted with 6%
acetone in hexanes. Fractions 18 to 29 were combined and dissolved in
acetone, decolorized with charcoal, and recrystallized from acetone. 1.0 g of a
crystalline mixture of the 7-epimers of 7,17-dimethyltestosterone was
obtained melting at 120° to 140°C.
The 7α-isomer are separated according to following procedure:
To obtain the 7(α)-isomer of 7,17-dimethyltestosterone the crystalline mixture
of the 7 stereoisomers of 7,17-dimethyltestosterone was refluxed in tertiary
butyl alcohol with recrystallized chloranil under nitrogen. The reaction mixture
was concentrated under a fast stream of nitrogen, diluted with methylene
chloride and the solution washed with dilute sodium hydroxide, water and
then dried, filtered and the solvent removed. The residue, was combined with
the product from an identical run and chromatographed through a magnesium
silicate column developed with solvent of the following composition and order:
two each of hexane hydrocarbons (Skellysolve B), hexanes plus 4% acetone,
hexanes plus 8% acetone, hexanes plus 12% acetone, hexanes plus 14%
acetone, hexanes plus 16% acetone, hexanes plus 18% acetone, hexanes
plus 20% acetone, hexanes plus 24% acetone, hexanes plus 28% acetone,
and two of acetone.
The residues, eluted with mixture: water-acetone, were combined and
chromatographed through a 50 g 1:1 charcoal (Darco)-diatomaceous earth
(Celite) column. The column was developed with solvent of the following
composition and order: methanol, a 1:1 mixture of methanol and acetone, a
1:2 mixture of methanol and acetone, acetone and a 1:4 mixture of acetone
and methylene chloride. Fractions, containing 7(α)-epimer were combined, the
solvent evaporated and the residue crystallized from acetone to give the
7α,17-dimethyltestosterone, melting point at 163° to 165°C.
Therapeutic Function
Anabolic
Check Digit Verification of cas no
The CAS Registry Mumber 1605-89-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,6,0 and 5 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1605-89:
(6*1)+(5*6)+(4*0)+(3*5)+(2*8)+(1*9)=76
76 % 10 = 6
So 1605-89-6 is a valid CAS Registry Number.
InChI:InChI=1/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16+,17+,18-,19+,20+,21+/m1/s1
1605-89-6Relevant articles and documents
ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
-
, (2008/06/13)
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.
Method for androgen supplementation
-
, (2008/06/13)
A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.
